Given Brainomix's success in developing imaging biomarkers for Stroke and Interstitial Lung Disease (ILD), future research and development will expand the Brainomix 360 platform to include a Cancer solution, with a focus on improving treatment response assessment in Oncology.

Brainomix’s Cancer solution has been trained to characterize and quantify solid-tumors using thousands of cases from leading academic institutions, unlocking objective measurement of tumor lengths, and other biomarkers such as tumor volume.